Phase I Evaluation of ΔvirG Shigella sonnei Live, Attenuated, Oral Vaccine Strain WRSS1 in Healthy Adults
View/ Open
Issue Date
2002-04Author
Kotloff, Karen L.
Taylor, David N.
Sztein, Marcelo B.
Wasserman, Steven S.
Losonsky, Genevieve
Katz, David E.
Campbell, James D.
Levine, Myron M.
Hale, Thomas L.
Publisher
American Society for Microbiology
Type
Article
Article Version
Scholarly/refereed, publisher version
Rights
Copyright © 2002, American Society for Microbiology
Metadata
Show full item recordAbstract
We conducted a phase I trial with healthy adults to evaluate WRSS1, a live, oral ΔvirG Shigella sonnei vaccine candidate. In a double-blind, randomized, dose-escalating fashion, inpatient volunteers received a single dose of either placebo (n = 7) or vaccine (n = 27) at 3 × 103 CFU (group 1), 3 × 104 CFU (group 2), 3 × 105 CFU (group 3), or 3 × 106 CFU (group 4). The vaccine was generally well tolerated, although a low-grade fever or mild diarrhea occurred in six (22%) of the vaccine recipients. WRSS1 was recovered from the stools of 50 to 100% of the vaccinees in each group. The geometric mean peak anti-lipopolysaccharide responses in groups 1 to 4, respectively, were 99, 39, 278, and 233 for immunoglobulin (IgA) antibody-secreting cell counts; 401, 201, 533, and 284 for serum reciprocal IgG titers; and 25, 3, 489, and 1,092 for fecal IgA reciprocal titers. Postvaccination increases in gamma interferon production in response to Shigella antigens occurred in some volunteers. We conclude that WRSS1 vaccine is remarkably immunogenic in doses ranging from 103 to 106 CFU but elicits clinical reactions that must be assessed in further volunteer trials.
Collections
Citation
Kotloff, K. L., Taylor, D. N., Sztein, M. B., Wasserman, S. S., Losonsky, G. A., Nataro, J. P., … Hale, T. L. (2002). Phase I Evaluation of ΔvirG Shigella sonnei Live, Attenuated, Oral Vaccine Strain WRSS1 in Healthy Adults . Infection and Immunity, 70(4), 2016–2021. http://doi.org/10.1128/IAI.70.4.2016-2021.2002
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.